Refractory malignant neoplasm

This phase II trial is testing whether a combination of two drugs, rigosertib and pembrolizumab, can help people with advanced melanoma that no longer responds to standard immunotherapy. The study involves 7 participants with unresectable or metastatic melanoma. The goal is to se…

This study tests a new drug, CBX-12, in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors and how safe it is at two different dose levels given every three weeks. Participants must have a specif…

This early-phase study tests a portable device that sends gentle electric fields to the liver, combined with chemotherapy and a targeted drug (bevacizumab), in people whose cancer has spread to the liver and stopped responding to standard treatments. The main goal is to find the …

This early-stage trial tests the safety and best dose of the drug neratinib when combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have certain gene mutations or amplifications. The study enrolls 93 participa…

This early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…

This early-phase trial tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and alpelisib (a targeted therapy)—in patients with triple-negative breast cancer that had specific genetic changes (PIK3CA or PTEN) and didn't respond to standard treatment. The goal was to …

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This study tested whether adding an experimental drug (VIC-1911) to the standard drug lenvatinib could help people with liver cancer that no longer responds to lenvatinib alone. Only 5 people were enrolled before the study was stopped early. The goal was to see if the combination…

This early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…

This early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so r…

This phase II trial tested a mix of a personalized dendritic cell vaccine and three immune-boosting drugs in people with advanced melanoma that no longer responded to PD-1/PD-L1 checkpoint inhibitors. The goal was to see if the combination could shrink tumors or slow their growth…

This study looked at how platinum-resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers surveyed 24 patients and their caregivers using questionnaires to measure symptoms, daily challenges, and overall well-being. The goal wa…